An Overview of the Randomized Placebo-Controlled Trials of Chinese Herbal Medicine Formula Granules

Table 2

Comparison of the cure rate between CHM formula granules and placebo.

Study ID	Treatment		Placebo		P value
	n/N	%	n/N	%
HBV carrier: HBV DNA negative after 48-week treatment
He JS 2012	1/174	0.57	0/93	0.00	0.77
Li HZ 2012	3/191	1.57	0/94	0.00	0.35
Ni W 2015	3/40	7.50	0/20	0.00	0.41
Xing YF 2012	3/191	1.57	1/187	0.53	0.38
Meta-analysis RR and 95% CI: 2.97 ; I^2 = 0%
HBV carrier: HBeAg negative after 48-week treatment
He JS 2012	11/174	6.32	3/93	3.23	0.29
Li HZ 2012	7/191	3.66	3/94	3.19	0.84
Ni W 2015	5/40	12.50	1/20	5.00	0.38
Zheng YJ 2012	6/56	10.71	2/57	3.51	0.15
Meta-analysis RR and 95% CI: 1.99 ; I^2 = 0%
HBV recrudescence: HBV DNA negative after 48-week treatment
Zhang ZE 2013	9/23	39.13	1/23	4.35	0.02
HBV recrudescence: HBeAg negative after 48-week treatment
Zhang ZE 2013	7/23	30.43	2/23	8.70	0.08
Chronic hepatitis C: HCV RNA negative after 48-weektreatment and 24-week follow-up
Zhao L 2014 (HCV-1b)	4/44	9.09	0/51	0.00	0.11
Zhao L 2014 (HCV-other)	6/14	42.86	1/15	6.67	0.04
Zhao L 2014-1	10/60	16.67	3/68	4.41	0.03
Meta-analysis RR and 95% CI: 6.26 ; I^2 = 0%
Non-alcoholic fatty liver disease: Normal ALT and B-ultrasound after 12-week treatment
Cheng Y 2017	19/40	47.50	10/40	25.00	0.04
Depression: Reduction in Edinburgh Postnatal Depression Scale (EPDS)≥80
Xu F 2013-1	13/50	26.00	4/50	8.00	0.02
Xu F 2013	14/45	31.11	6/45	13.33	0.05
Fever: Normal temperature and resolution of cold symptoms
Cheng Y 2016	27/41	65.85	18/40	45.00	0.06
Xie JH 2017	29/48	60.42	17/48	35.42	0.02
Meta-analysis RR and 95% CI: 2.58 ; I^2 = 0%
Migraine: Resolution of symptoms after 12-week treatment and at 2-month follow-up
Xu YL 2011	4/24	16.67	0/24	0.00	0.12